ADORA2A

Across TCGA pan-cancer cohorts, ADORA2A RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of ADORA2A’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where ADORA2A RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ADORA2A is over-expressed in tumor, although a few such as KICH and COAD show the opposite, repressed pattern.

KIRC, KICH, and LIHC are the cancer types where ADORA2A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ADORA2A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	III,IV	+0.410	<.001	12	view →
KICH	Male	All	−0.333	<.001	10	view →
LIHC	Male	All	+0.520	<.001	8	view →
COAD	All	III,IV	−0.183	<.001	8	view →
LUAD	All	II,III,IV	−0.177	.002	7	view →
BRCA	All	II,III,IV	+0.225	<.001	6	view →
KIRP	Male	All	−0.224	<.001	6	view →
LUSC	Female	All	−0.392	<.001	5	view →
THCA	All	All	−0.103	.002	5	view →
CHOL	All	All	−0.387	.002	4	view →
HNSC	All	II,III,IV	+0.055	.009	4	view →
UCEC	All	All	−0.084	.003	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

ADORA2A–KIRC

Open the KIRC breakdown →